Last reviewed · How we verify
Paclitaxel + Carboplatine
Paclitaxel and carboplatin work synergistically to kill cancer cells by stabilizing microtubules and causing DNA damage, respectively.
Paclitaxel and carboplatin work synergistically to kill cancer cells by stabilizing microtubules and causing DNA damage, respectively. Used for Non-small cell lung cancer (NSCLC), Ovarian cancer, Breast cancer.
At a glance
| Generic name | Paclitaxel + Carboplatine |
|---|---|
| Sponsor | Intergroupe Francophone de Cancerologie Thoracique |
| Drug class | Chemotherapy combination (taxane + platinum agent) |
| Target | β-tubulin (paclitaxel); DNA (carboplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel is a taxane that binds to β-tubulin and stabilizes microtubules, preventing their disassembly and disrupting cell division. Carboplatin is a platinum-based alkylating agent that forms DNA crosslinks, causing double-strand breaks and apoptosis. Together, they provide complementary cytotoxic mechanisms effective against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Ovarian cancer
- Breast cancer
- Other solid tumors
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Nausea and vomiting
- Alopecia
- Fatigue
- Hypersensitivity reactions
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: